Matthew Yglesias @mattyglesias
@JInterlandi @davidalim Fair enough! But I think that still supports the view that the test abundance gap is driven by regulatory differences. FDA is very reluctant to approve tests that maybe don't work — not a crazy idea, but that makes it a lot harder to get tests on the market. — PolitiTweet.org
